Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 10/20 | 0.55 |
| ▸ | MAOB | P27338 | 2/20 | 0.51 |
| ▸ | F12 | P00748 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4721074 | 0.84 | NR1H4 (0.58) | RAB9ASMN1; SMN2ALDH1A1NPC1MAPT | |
| SCHEMBL4724325 | 0.80 | RAB9A (0.49) | KMT2AMEN1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL18160306 | 0.77 | HDAC8 (0.68) | F10MAOBF12KMT2AMEN1 | |
| SCHEMBL4720399 | 0.76 | MEN1 (0.53) | KMT2AMEN1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL24460276 | 0.76 | P2RX1 (0.77) | F10MAOBF12KMT2AMEN1 | |
| SCHEMBL6589803 | 0.74 | FADS1 (0.58) | F10MAOBF12KMT2AMEN1 | |
| SCHEMBL14055333 | 0.74 | F10 (0.64) | F10MAOBF12KMT2AMEN1 | |
| SCHEMBL2681276 | 0.74 | RAB9A (0.69) | KMT2AMEN1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL23486513 | 0.73 | KDM4E (0.43) | MAOBKMT2AMEN1RAB9ASMN1; SMN2 | |
| SCHEMBL21914835 | 0.70 | P2RX1 (0.62) | KMT2ARAB9ASMN1; SMN2ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928843-A1 | BIS-ARYL UREA COMPOUNDS FOR THE TREATMENT OF PROTEIN KINASE-MEDIATED DISEAES | Amgen, Inc (US) | 2008-06-11 | — | — | EP | claimed |
| WO-2007024754-A1 | BIS-ARYL UREA COMPOUNDS FOR THE TREATMENT OF PROTEIN KINASE-MEDIATED DISEAES | AMGEN INC. (US) | 2007-03-01 | — | — | WO | claimed |
| US-20070049592-A1 | Bis-aryl urea compounds and methods of use | AMGEN INC. | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049592-A1 | Bis-aryl urea compounds and methods of use | TIE1, KDR, BDKRB2 | F10 1448/4885MAOB 710/4885F12 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.